Brandywine Global Investment Management LLC Acquires Shares of 74,550 Halozyme Therapeutics, Inc. $HALO

Key Points

• Brandywine Global Investment Management LLC made a new investment of approximately $4.76 million in Halozyme Therapeutics, acquiring 74,550 shares during the first quarter.
• Insider trading revealed that CEO Helen Torley sold 20,000 shares at an average price of $63.51, reducing her ownership stake by 2.65%.
• Recent analyst ratings show a mix of opinions on Halozyme Therapeutics, with Wells Fargo raising the price target to $65.00 while Leerink Partners downgraded it to a "strong sell" with a $47.00 objective.

Brandywine Global Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 74,550 shares of the biopharmaceutical company's stock, valued at approximately $4,757,000. Brandywine Global Investment Management LLC owned about 0.06% of Halozyme Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Penserra Capital Management LLC acquired a new position in Halozyme Therapeutics during the first quarter valued at approximately $125,000. Bessemer Group Inc. grew its holdings in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 207 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after purchasing an additional 524,802 shares during the last quarter. Fifth Third Bancorp grew its holdings in Halozyme Therapeutics by 29.4% during the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after purchasing an additional 2,276 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 199.0% during the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after purchasing an additional 1,865 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. JMP Securities increased their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 6th. Leerink Partners cut Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a research report on Tuesday, May 13th. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective for the company. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $67.11.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 80,000 shares of company stock worth $4,532,600 over the last three months. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

HALO stock traded up $0.48 during midday trading on Thursday, hitting $71.61. The stock had a trading volume of 1,863,714 shares, compared to its average volume of 1,962,804. The firm has a market capitalization of $8.38 billion, a price-to-earnings ratio of 16.39, a P/E/G ratio of 0.38 and a beta of 1.17. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $72.33. The stock has a 50-day simple moving average of $58.02 and a 200 day simple moving average of $58.53. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period last year, the business earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.